CytoReason announced a collaboration with Merck KGaA to profile one of its leading immuno-oncology drugs. Multiple drugs created to cure the same disease have varying effects on certain patient populations depending on the drug's mechanism of action (MoA) and on patients' characteristics. CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck KGaA, Darmstadt, Germany's therapeutic hypothesis, providing a deeper analysis of the drug's MoA. The company will analyze data from hundreds of patients from phase 1 and 2 studies to identify relevant patient populations, as well as prioritize tumor types for which the drug may be most effective against.